Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.73 |
| ▸ | RARA | P10276 | 8/20 | 0.73 |
| ▸ | RARB | P10826 | 8/20 | 0.73 |
| ▸ | RXRG | P48443 | 8/20 | 0.73 |
| ▸ | RXRB | P28702 | 7/20 | 0.73 |
| ▸ | RARG | P13631 | 5/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HNF4A | P41235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073361 | 0.89 | RXRA (0.77) | RXRARARARARBRXRGRXRB | |
| SCHEMBL29434832 | 0.85 | RXRA (1.00) | RXRARARARARBRXRGRXRB | |
| SCHEMBL29357483 | 0.85 | RXRA (1.00) | RXRARARARARBRXRGRXRB | |
| SCHEMBL13752425 | 0.85 | RXRA (0.82) | RXRARARARARBRXRGRXRB | |
| SCHEMBL301213 | 0.85 | RXRA (1.00) | RXRARARARARBRXRGRXRB | |
| SCHEMBL21549712 | 0.80 | RXRA (0.74) | RXRARARARARBRXRGRXRB | |
| SCHEMBL7023688 | 0.78 | RXRA (0.71) | RXRARARARARBRXRGRXRB | |
| SCHEMBL20411358 | 0.78 | RXRA (0.61) | RXRARARARARBRXRGRXRB | |
| SCHEMBL6033264 | 0.77 | RARA (0.48) | RXRARARARARBRXRGRXRB | |
| SCHEMBL1073669 | 0.77 | RXRA (0.74) | RXRARARARARBRXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RARA 7/4885RARB 6/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RARA 18/4885RARB 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.